Mereo BioPharma (MREO) Non-Current Debt (2017 - 2023)

Mereo BioPharma (MREO) posted quarterly Non-Current Debt of $4.6 million for Q2 2023, down 76.35% quarter-over-quarter from $19.4 million in Q4 2021.

Mereo BioPharma (MREO) Non-Current Debt (2017 - 2023) Analysis & Trends

Mereo BioPharma (MREO) has reported Non-Current Debt for 6 consecutive years, with $4.6 million the latest figure, recorded in Q2 2023.

In Q2 2023, Non-Current Debt changed N/A year-over-year to $4.6 million; the TTM figure through Jun 2023 stood at $4.6 million (changed N/A YoY), while the FY2021 annual figure was $19.4 million, down 9.03% from the prior year.
Non-Current Debt slipped to $4.6 million in Q2 2023 per MREO's latest filing, from $19.4 million in the prior quarter.
Across five years, Non-Current Debt topped out at $25.1 million in Q2 2021 and bottomed at $4.6 million in Q2 2023.
Historically, Non-Current Debt has averaged $15.8 million across 4 years, with a median of $18.0 million in 2020.
Annual changes were most pronounced in 2019 — Non-Current Debt tumbled 63.35% — and 2020, when it jumped 208.54%.
Mereo BioPharma's Non-Current Debt stood at $6.9 million in 2019, then surged by 208.54% to $21.3 million in 2020, then dropped by 9.03% to $19.4 million in 2021, then sank by 76.35% to $4.6 million in 2023.
Business Quant data shows MREO's Non-Current Debt at $4.6 million in Q2 2023, $19.4 million in Q4 2021, and $25.1 million in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.20 Bn	131.35 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.09 Bn	78.10 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.25 Bn	60.07 Bn	1.37 Bn	-
4	Moderna	59.04 Bn	53.90 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.04 Bn	36.94 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.61 Bn	28.30 Bn	992.69 Mn	-
7	BioNTech SE	28.04 Bn	9.65 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.50 Bn	26.33 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.34 Bn	26.50 Bn	-	8.96 Bn
10	Mereo BioPharma	47.14 Mn	47.14 Mn	-	-

Download Data